Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
Some practitioners theorize that establishing robust GLP-1-supporting gut bacteria before discontinuing medication could provide a partial buffer against rebound effects, maintaining some degree of natural GLP-1 production even after the pharmaceutical support is removed
One things clear Weight loss is about a lot more than incretins like GLP-1
Singh, Vats P, Singh SN, Singh SB
